PURPOSE: Hypoxia is associated with tumor aggressiveness and is an important cause of resistance to radiation therapy and chemotherapy. Assays of tumor hypoxia could provide selection tools for hypoxia-modifying treatments. The purpose of this study was to develop and characterize a rodent tumor model with a reporter gene construct that would be transactivated by the hypoxia-inducible molecular switch, i.e., the upregulation of HIF-1. METHODS: The reporter gene construct is the herpes simplex virus 1-thymidine kinase (HSV1-tk) fused with the enhanced green fluorescent protein (eGFP) under the regulation of an artificial hypoxia-responsive enhancer/promoter. In this model, tumor hypoxia would up-regulate HIF-1, and through the hypoxia-responsive promoter transactivate the HSV1-tkeGFP fusion gene. The expression of this reporter gene can be assessed with the 124I-labeled reporter substrate 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-iodouracil (124I-FIAU), which is phosphorylated by the HSV1-tk enzyme and trapped in the hypoxic cells. Animal positron emission tomography (microPET) and phosphor plate imaging (PPI) were used in this study to visualize the trapped 124I-FIAU, providing a distribution of the hypoxia-induced molecular events. The distribution of 124I-FIAU was also compared with that of an exogenous hypoxic cell marker, 18F-fluoromisonidazole (FMISO). RESULTS: Our results showed that 124I-FIAU microPET imaging of the hypoxia-induced reporter gene expression is feasible, and that the intratumoral distributions of 124I-FIAU and 18F-FMISO are similar. In tumor sections, detailed radioactivity distributions were obtained with PPI which also showed similarity between 124I-FIAU and 18F-FMISO. CONCLUSION: This reporter system is sufficiently sensitive to detect hypoxia-induced transcriptional activation by noninvasive imaging and might provide a valuable tool in studying tumor hypoxia and in validating existing and future exogenous markers for tumor hypoxia.
PURPOSE:Hypoxia is associated with tumor aggressiveness and is an important cause of resistance to radiation therapy and chemotherapy. Assays of tumor hypoxia could provide selection tools for hypoxia-modifying treatments. The purpose of this study was to develop and characterize a rodent tumor model with a reporter gene construct that would be transactivated by the hypoxia-inducible molecular switch, i.e., the upregulation of HIF-1. METHODS: The reporter gene construct is the herpes simplex virus 1-thymidine kinase (HSV1-tk) fused with the enhanced green fluorescent protein (eGFP) under the regulation of an artificial hypoxia-responsive enhancer/promoter. In this model, tumor hypoxia would up-regulate HIF-1, and through the hypoxia-responsive promoter transactivate the HSV1-tkeGFP fusion gene. The expression of this reporter gene can be assessed with the 124I-labeled reporter substrate 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-iodouracil (124I-FIAU), which is phosphorylated by the HSV1-tk enzyme and trapped in the hypoxic cells. Animal positron emission tomography (microPET) and phosphor plate imaging (PPI) were used in this study to visualize the trapped 124I-FIAU, providing a distribution of the hypoxia-induced molecular events. The distribution of 124I-FIAU was also compared with that of an exogenous hypoxic cell marker, 18F-fluoromisonidazole (FMISO). RESULTS: Our results showed that 124I-FIAU microPET imaging of the hypoxia-induced reporter gene expression is feasible, and that the intratumoral distributions of 124I-FIAU and 18F-FMISO are similar. In tumor sections, detailed radioactivity distributions were obtained with PPI which also showed similarity between 124I-FIAU and 18F-FMISO. CONCLUSION: This reporter system is sufficiently sensitive to detect hypoxia-induced transcriptional activation by noninvasive imaging and might provide a valuable tool in studying tumor hypoxia and in validating existing and future exogenous markers for tumor hypoxia.
Authors: J S Rasey; W J Koh; M L Evans; L M Peterson; T K Lewellen; M M Graham; K A Krohn Journal: Int J Radiat Oncol Biol Phys Date: 1996-09-01 Impact factor: 7.038
Authors: V Ponomarev; M Doubrovin; C Lyddane; T Beresten; J Balatoni; W Bornman; R Finn; T Akhurst; S Larson; R Blasberg; M Sadelain; J G Tjuvajev Journal: Neoplasia Date: 2001 Nov-Dec Impact factor: 5.715
Authors: D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701
Authors: Farrokh Dehdashti; Mark A Mintun; Jason S Lewis; Jeffrey Bradley; Ramaswamy Govindan; Richard Laforest; Michael J Welch; Barry A Siegel Journal: Eur J Nucl Med Mol Imaging Date: 2003-04-12 Impact factor: 9.236
Authors: Pat Zanzonico; Joseph O'Donoghue; J Donald Chapman; Richard Schneider; Shangde Cai; Steven Larson; Bixiu Wen; Yuchun Chen; Ronald Finn; Shutian Ruan; Leo Gerweck; John Humm; Clifton Ling Journal: Eur J Nucl Med Mol Imaging Date: 2003-10-02 Impact factor: 9.236
Authors: David L Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William Bornmann; Juri Gelovani Journal: Mol Cancer Ther Date: 2009-04 Impact factor: 6.261
Authors: David L Schwartz; James Bankson; Luc Bidaut; Yi He; Ryan Williams; Robert Lemos; Arun Kumar Thitai; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Hsin-Hsien Yeh; Ryuichi Nishii; Uday Mukhopadhay; Mian Alauddin; Ioseb Mushkudiani; Norihito Kuno; Sunil Krishnan; William Bornman; Stephen Y Lai; Garth Powis; John Hazle; Juri Gelovani Journal: Mol Cancer Res Date: 2011-03-01 Impact factor: 5.852
Authors: Bixiu Wen; Muneyasu Urano; John L Humm; Venkatraman E Seshan; Gloria C Li; C Clifton Ling Journal: Radiat Res Date: 2008-01 Impact factor: 2.841